| --- | --- | |-------------------------------------------------------------|-------| | | | | Q3 2020 results | | | webcast | | | Onno van de Stolpe, CEO Piet Wigerinck, CSO 6 November 2020 | | | | | Disclaimer This presentation contains forward-looking statements, including (without limitation) statements concerning the progress of our clinical pipeline, the statements regarding the global R&D collaboration with Gilead, statements relating to interactions with regulatory authorities, the timing or likeliho ...